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Background: Primary ciliary dyskinesia (PCD) is a genetic disease characterized by
abnormally beating cilia. In these patients, levels of nasal nitric oxide (nNO) are lower than
those observed in healthy subjects.
Objectives: We identify the nNO levels in healthy pre-school uncooperative children and
in PCD patients, in order the application of nNO measurement in the early identiﬁcation of
young children with PCD.
Methods: We measured nNO in 77 healthy children (50 uncooperative and 27 cooperative)
and in 10 PCD patients. Fifteen cooperative healthy children were also asked to perform an
uncooperative test.
Results: PCD patients presented low nNO levels (29.775.7 ppb) compared to those
observed in healthy children (358.8735.2 ppb; po0.05). nNO levels were increased in
healthy cooperative children (650760.6 ppb; po0.05) as compared to those uncoopera-
tive aging more than 6 month (309.1745.9 ppb; po0.05) or less (128.1716.2 ppb;
po0.05). Twenty-four uncooperative children with nNO values p200 ppb performed a
second evaluation at least 6 months later and mean levels increased from 104.7710.5 ppb
to 169.9719.6 ppb (po0.05). In the 15 collaborative children nNO levels were higher
during the breath holding manoeuvre (687.7796.9 ppb) than during the tidal breathing
manoeuvre (335.9757.9 ppb; po0.05).
Conclusions: Healthy children have higher nNO levels than PCD patients. In 15% of
uncooperative healthy children can be found low nNO levels, similar to PCD patients, but
those values increased some months later, in successive evaluations. Nasal NO may be used
for PCD screening even though repeated evaluations may be necessary in young children.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Primary ciliary dyskinesia (PCD) is a genetic disease
characterized by defective motility of cilia, in most cases
related to an ultrastructural defect,1 which results in
impaired mucociliary clearance of the upper and lower
airways2 associated with recurrent-chronic respiratory
symptoms.1,3
Since respiratory symptoms are also common in healthy
children and the disease is relatively rare (1 in 15–30,000
live births, in white population), the diagnosis of PCD is
often missed for a long time.4 Furthermore, diagnostic
investigations such as the demonstration of ultrastructural
defect at transmission electron microscopy and ciliary
motion analysis require both expertise and laboratory
facilities which are not widely available.
In order to prevent lung function deterioration due to
inadequate treatment, an early identiﬁcation of PCD
patients is warranted.5,6 Since nNO level in PCD patients
has been observed to be 80–90% lower than in healthy
controls,7–15 including affected infants,16,17 this para-
meter could provide useful ﬁrst-line information in the
diagnostic algorithm of PCD. Nevertheless, while normal
values are available for school aged children,18 reference
values are lacking in pre-school aged children and infantsTable 1 Signs and symptoms suggestive of PCD.2,3
Neonatal period:
 respiratory distress or pneumonia in term neonates
with no obvious predisposing cause
 rhinitis and/or nasal congestion that remain constant
over time
 situs inversus
 moist sounding cough is unusual in this period but
suggestive
 complex congenital heart disease, esophageal and
biliary atresia, hydrocephalus
 positive family history of PCD
Infant and older child:
 chronic cough with sputum production
 rhinosinusitis
 chronic secretory otitis media with prolonged
otorrhoea after tympanostomy
 pneumonia
 bronchiectasis
 repeated courses of antibiotics for chest infections
 atypical asthma refractory to treatment
Adults:
 as for older children with reduced importance of otitis
media
 subfertility or infertility in male
 ectopic pregnancywho cannot perform the nNO test according to ERS/ATS
guideline.19
The aim of this study was to identify the nNO levels in
healthy infants and pre-school children devoid of signs and
symptoms suggestive of ciliary dyskinesia (Table 1). A
particular regard was dedicated to methodological issues
in these uncooperative subjects, in order to better address
the potential application of nNO measurement in the early
identiﬁcation of young children with PCD.
Patients and methods
Subjects
A total of 87 subjects participated to the study. Of these, 10
patients (7 males, mean 17 years) with PCD, two of whom
were uncooperative children, diagnosed by electron micro-
scopy2,20 served as positive controls. Main clinical features
for these patients are summarized in Table 2. Seventy-seven
subjects were healthy children (46 males, 31 females), 50 of
which were uncooperative infants aged less than 6 months
(n ¼ 26) or between 6 and 12 months (n ¼ 24) and 27 were
school-aged children (mean 7 years) able to perform the test
procedures according to guidelines.19
The subjects were selected among those who had never
received inhaled corticosteroids or nasal decongestant drugs
and did not have adeno- or tonsillectomy.
The measurements were part of routine clinical evalua-
tion.
Nasal NO measurements
Exhaled nasal nitric oxide (nNO) level was measured by
inserting a nNO-inert olive in one nostril, completely
occluding the nostril to avoid ambient air sampling.18,19
The controlateral nostril was left open. The olive was
connected via a Teﬂons tube at the analyser and the nasal
air was sampled continuously with a constant trans-
nasal aspiration ﬂow of 300mLmin1.19,21 The nNOTable 2 PCD patients’ characteristics.
Patients
no.
Situs
inversus
(yes/no)
Bronchiectasis
(yes/no)
Sinusitis
(yes/no)
Cilia
ultrastructural
defect
1; c N Y Y I-ODA
2; c N Y N I-ODA
3; u Y N N IDA
4; c N Y N I-ODA
5; c Y Y N I-ODA
6; c N Y N IDA
7; c N Y N ODA
8; c N Y N I-ODA
9; c Y Y Y I-ODA
10; u Y N N I-ODA
c, cooperatine; u, uncooperative; I-ODA, inner and/or outer
dynein arms.
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analyser (Aerocrine, Stockolm, Sweden), which was cali-
brated at least every 14 days using certiﬁed calibration gas
(NO, 1460 ppb). The nNO signal was sent to a computer data
acquisition program (NIOX, nasal mode; Aerocrine) that
displayed real-time measurements.18
Cooperative children were asked to take a deep breath
and hold it for 10 s while the average nNO concentration was
calculated at the plateau between 7 and 10 s after breath-
hold according to ERS and ATS guidelines.19 Moreover, 15 of
these cooperative subjects were asked to perform an
uncooperative test mimicking the condition of infants, i.e.
the nasal sampling was performed continuously for 30 s
during tidal breathing as it was done for the uncooperative
infant group. For all subjects the manoeuvre was performed
in triplicate. Measurement of ambient NO concentration was
recorded every day.Figure 1 Individual values of exhaled nNO levels in PCD patients
cooperative school-aged children. Horizontal lines represent meanStatistical analysis
Data are presented as mean7standard error of the
mean (X7SEM). Between groups comparisons were per-
formed by ANOVA for multiple sample comparison. Paired
t-test was used for the comparison within the group of
cooperative children when performing the nNO measure-
ment according to the guidelines as compared to mimicking
the condition of infants. A p value of o0.05 was considered
signiﬁcant.
The accuracy of the test was calculated according to the
following formulas:, in
valSensitivity (Se) ¼ True positives/(true positives+false posi-
tives) 100. Speciﬁcity (Sp) ¼ True negatives/(true negatives+false posi-
tives) 100.healthy children aging more or less than 6 months and in
ue.
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(paPositive predictive value (PPV) ¼ True positives/(true
positives+false positives) 100. Negative predictive value (NPV) ¼ True negatives/(false
positives+True negatives) 100. Receiver operating characteristic (ROC) curves for eNO
were constructed.
Results
nNO measurements were performed in all the children and
no adverse event was observed. When healthy subjects were
considered altogether (n ¼ 77), independently from the age
and from their ability to perform the test according to
guidelines (methods A or B), nNO values ranged from 10.6 to
1456 ppb (mean 358.8735.2 ppb). In the 10 subjects with
PCD the nasal NO levels range was from 6.7 to 66.7 ppb with
a mean values of 29.775.9 ppb, being signiﬁcantly lower
than the mean value of the whole group of all healthy
children (po0.005). The two infants with PCD had,
respectively, nNO values of 7.2 and 41.6 ppb. All individual
data measured in children are presented in Figure 1.
Considering the whole group, ROC curves indicated that,
in our study group, a nNO value of 68 ppb had the best
combination of sensitivity and speciﬁcity for predicting the
diagnosis of PCD (Se ¼ 100%, Sp ¼ 90%) (Figure 2, panel A).
The PPV and NPV values of nNO of 68 ppb were 56% and
100%, respectively.
When the healthy population was analysed by ANOVA
comparing the two subgroups of uncooperative children and
the group of cooperative school aged subjects, a signiﬁcant
difference among groups was observed (po0.01). The
subgroup of cooperative school aged children (n ¼ 26) had
a mean nNO level of 650760.6 ppb, which was signiﬁcantly
higher than in uncooperative healthy children either aging
more than 6 months (309.1745.9 ppb, po0.05) or less than
6 months (128.1716.2 ppb, po0.05).
Considering the group of cooperative healthy children the
ROC curves indicated that, in our study population, a nNO
value of 71 had a combination of Se ¼ 100% and SP ¼ 100%
for excluding the diagnosis of PCD (Figure 2, panel B). As a
consequence, the PPV and NPV values for nNO cutoff of
71 ppb were both 100%. Excluding the uncooperativeure 2 ROC curves for nNO for PCD patients and the whole gro
nel B) and healthy infants below 6 months of age (panel C).children from the group of PCD patients (n ¼ 2) and
considering the cooperative PCD children (n ¼ 8) as com-
pared to all the healthy children, ROC maintained the same
characteristics.
In the whole group of uncooperative children below the
age of 12 months, 4 out of the 50 (8%) showed nNO values
o50 ppb (with cut-off value 50 ppb: Se ¼ 90%, Sp ¼ 92%,
PV+ ¼ 69%, PV ¼ 98%) while 12 (24%) had nNO values
o100 ppb (with cut-off value 100 ppb Se ¼ 100%, Sp ¼ 76%,
PV+ ¼ 45%, PV ¼ 100%).
Also in this group, ROC curves indicated that a nNO value
of 68 had the best combination of sensitivity and speciﬁcity
for excluding the diagnosis of PCD (Se ¼ 100%, Sp ¼ 84%).
The PPV and NPV values for nNO cutoff of 68 ppb were 56%
and 100%, respectively. No signiﬁcant difference was shown
in the comparison of the ROC curve from this group versus
the one from cooperative children.
As signiﬁcant difference in nNO levels was also observed
between uncooperative children aged less than 6 months vs
more those aged 6 to 12 months (po0.05), a separate
analysis to assess the accuracy of test in the youngest group
was performed. In this group, the percentage of false
positives was higher, being 15% (4 out 26) with cut-off value
of 50 ppb (Se ¼ 90%, Sp ¼ 85%, PV+ ¼ 69%, PV ¼ 96%) and
38% (10 out of 26) with cut-off value of 100 ppb (Se ¼ 100,
Sp ¼ 61%, PV+ ¼ 53%, PV ¼ 100%). In this subgroup, ROC
curves indicate that a nNO value of 54 ppb had the best
combination of sensitivity and speciﬁcity for predicting the
diagnosis of PCD (Se ¼ 90%, Sp ¼ 81%) (Figure 2, panel C).
The PPV and NPV values of nNO cutoff of 54 ppb were 64%
and 95%, respectively. A comparison of the ROC curve
obtained considering all the cooperative children versus the
uncooperative aged below 6 months showed a signiﬁcant
difference (AUC 1 vs 0.89; Kendal-Tau ¼ 0; Z ¼ 2.045).
In order to assess a possible effect of the age in the
uncooperative healthy children, 24 of the 28 with nNO lower
than 200 ppb were re-evaluated after 6–8 months from the
ﬁrst measurement. In these subjects, nNO signiﬁcantly
increased from 104.7710.5 ppb to 169.9719.6 ppb
(po0.05) (Figure 3). The same re-evaluation after 6–8
months was performed also in the two non-cooperative
children with PCD. For these patients the nNO values were
41.6 and 7.2 ppb at the ﬁrst measurement. At the secondup of healthy controls (panel A), cooperative healthy controls
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10 ppb, respectively.
In the 15 cooperative children who performed both the
standardized manoeuvre with 10 s of breath holding and the
manoeuvre without breath holding, mimicking the condition
of younger subjects, nNO levels were (687.7796.9 ppb
and 335.9757.9 ppb, respectively in the two different
experimental conditions (po0.05) (Figure 4). No healthyFigure 3 Individual values of nNO in young uncooperative
children performing two evaluations at least 6 months apart:
T0, ﬁrst evaluation and T1, second evaluation. Horizontal lines
represent mean value.
Figure 4 Individual values of exhaled nNO levels in healthy
cooperative children during the cooperative and uncooperative
manoeuvre. Horizontal lines represent mean value.school-aged children had nNO values less than 150 ppb when
performing the test as recommended by guidelines18 but 2 of
the 15 (13.3%) children had values lower than 100 ppb during
the uncooperative manoeuvre.Discussion
NO is synthesized by epithelial ciliated cells of the nasal
cavity and paranasal sinuses where, because of its high
concentration of several hundreds parts per million,4 it can
exert antibacterial and antiviral effects. This could be one
of the main mechanisms contributing to ensure sinus
sterility in healthy subjects. Furthermore, there is growing
evidence that NO plays a crucial role in the regulation of
ciliary airway motility22 and several studies have shown
lower levels of nNO in children with PCD as compared to
healthy age-matched subjects.7–15 Recently, low nNO have
also been reported in infants with PCD16,17 and in atypical
PCD patients with persistent abnormal ciliary motility but
lacking the classical ultrastructural defect.23 The body of
these recent reports reinforce the suggestion that nNO can
be used a screening tool for the early identiﬁcation of PCD
patients, thus reducing the necessity to perform electron
microscope or kinetic evaluation in a wide number of
patients for which the suspect of PCD could be reshufﬂed by
normal levels of nNO. Nevertheless, in presence of persisting
symptoms PCD needs to be ruled out with the above-
mentioned validated tools.
The results of the present study conﬁrm that the mean
level of nNO in school-aged children is similar to those
previously reported18 despite the use of diverse sampling
ﬂows, respectively, 300 and 700mLmin1. Different sam-
pling ﬂows have been used by different authors (Table 3) and
somehow complicates between-study comparison. Since
lower nNO ppb levels are obtained with higher aspiration
ﬂows,24 a standardization of sampling ﬂow is warranted in
order to address a threshold for normal values. Even with
the same operating procedures, including sampling ﬂow, the
results of our study show that in children below the age of 12
months the mean nNO levels is signiﬁcantly different from
cooperative subjects, with some values overlapping those of
PCD patients. This is particularly true for the group of
children younger than 6 months, who presented a mean nNO
level even lower than that observed in the subjects aged 6
to 12 months. Furthermore, all of the eight uncooperative
subjects with nNO values overlapping those of PCD patients
were in the group aged less than 6 months. This observation
is in agreement with previous ones which documented that
nasal NO excretion is considerably reduced in infants
compared to older children and adults and that it increases
both with increasing body weight25 and with postconcep-
tional age.26,27
Lower levels of nNO in younger children can be explained
by the fact that paranasal sinuses in infants are only
partially pneumatised with less sinus surface than older
children and therefore NO supply to the nasal cavity
might be lower than in older subjects. Furthermore, in our
study, low nNO levels were also observed when school-aged
cooperative children performed the test in an uncooperative
fashion, continuing tidal breathing without breath-holding
during sample collection. Since during tidal breathing the
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Table 3 Nasal NO output reported by several authors.
Author,
year (Ref.)
Sample ﬂow
(mLmin1)
Mean nasal NO
values (ppb)
Mean age
(years)
PDC
patients
Healthy
Baraldi,
200416 y
110 100 295 0.4
Karadag,
19997
240 97 664 10.8
Naragan,
20029
250 60.3 716 10.8
Horvath,
200410
250 54.5 663 34
Lundberg,
19948
800 4 221 7.7
Corbelli,
200413
1200 13.7 223.7 11.4
Stehling,
200617 y
– o5 171.1 0.08
Wodehouse,
200311
– 65.7 759.1 34.2
Grasemann,
199915
– 72.1 1195 23
Sample ﬂow not declared.
yCase report.
G.L. Piacentini et al.546nasal concentration of NO can be diluted by the air coming
from lower airways, which contains much lower concentra-
tions of NO, this could represent an additional explanation
for lower nNO in uncooperative younger children. Taken
together, these results recommend prudential interpreta-
tion of low levels of nNO in children below the age of 6
months, in whom low nNO levels could represent a false
positive ﬁnding. Moreover, low levels of nNO have been also
reported in patients with cystic ﬁbrosis,27–32 sinusitis,33–35
nasal polyps,36,37 panbronchiolitis,38 and HIV.39 It is there-
fore clear that nNO measurement needs to be interpreted
together with other relevant clinical ﬁndings (Table 1) and
that this test will only exclude the diagnosis of PCD if nNO is
elevated while low levels need to be carefully interpreted
and used as an indication for selecting patients for nasal
biopsy.4 In order to better identify potentially PCD affected
infants and to avoid inappropriate ultrastructural examina-
tions, a follow-up of nNO levels could be helpful. In fact the
data from the present study show that all the healthy
children who had an initial low level when retested some
months later showed signiﬁcant increase in nNO values,
whereas this was reported not to be the case for the
subjects with PCD.23
Furthermore, there was no age effect in nNO levels in our
patients with PCD, also conﬁrmed by the repetition of the
measurement after 6–8 months in the two non-cooperative
children. Therefore, these results suggest that repeated
measures are warranted when nNO is occasionally measured
in young infants.
The limitation of this study was the sample size of
patients with PCD, however, the ciliary dyskinesia is raredisease and further studies are required in order to
evaluation nNO levels in uncooperative children. However,
despite the small number of PCD subjects, the statistical
analysis showed highly signiﬁcant changes of the nasal NO
levels in the different studied populations.
In conclusion, high levels of nNO are supportive of PCD
diagnosis exclusion while low levels are indicative of the
disease also in uncooperative infants when they remain
persistently low and when other diseases have been excluded.Conﬂict of interest
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